Kamil Ali-Jackson Sells 1,841 Shares of Aclaris Therapeutics Inc. (ACRS) Stock
Aclaris Therapeutics Inc. (NASDAQ:ACRS) insider Kamil Ali-Jackson sold 1,841 shares of the firm’s stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total transaction of $45,399.06. Following the completion of the sale, the insider now owns 77,798 shares of the company’s stock, valued at approximately $1,918,498.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Kamil Ali-Jackson also recently made the following trade(s):
- On Friday, August 26th, Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 25.16 on Friday. The stock’s market cap is $538.80 million. Aclaris Therapeutics Inc. has a one year low of $10.99 and a one year high of $33.88. The stock has a 50 day moving average of $22.28 and a 200-day moving average of $20.05.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.01. Analysts anticipate that Aclaris Therapeutics Inc. will post ($2.61) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in ACRS. Vivo Capital LLC acquired a new stake in Aclaris Therapeutics during the first quarter valued at $79,427,000. Opaleye Management Inc. acquired a new stake in Aclaris Therapeutics during the first quarter valued at $341,000. EAM Investors LLC acquired a new stake in Aclaris Therapeutics during the second quarter valued at $668,000. Geduld E E raised its stake in Aclaris Therapeutics by 62.5% in the second quarter. Geduld E E now owns 17,500 shares of the company’s stock valued at $323,000 after buying an additional 6,729 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock valued at $536,000 after buying an additional 5,535 shares during the last quarter. Hedge funds and other institutional investors own 71.39% of the company’s stock.
ACRS has been the subject of several recent analyst reports. Jefferies Group raised their target price on shares of Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, September 19th. Guggenheim initiated coverage on shares of Aclaris Therapeutics in a report on Friday, June 10th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $31.25.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.